Curis, Inc. (NASDAQ:CRIS) Sees Large Growth in Short Interest

Posted by William Tyler on Jan 14th, 2025

Curis, Inc. (NASDAQ:CRIS – Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 81,700 shares, a growth of 82.0% from the December 15th total of 44,900 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average trading volume of 118,900 shares, the days-to-cover ratio is currently 0.7 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Curis in a report on Tuesday, December 10th.

Get Our Latest Stock Analysis on Curis

Curis Stock Down 4.5 %

Curis stock traded down $0.15 during mid-day trading on Tuesday, hitting $3.21. The company’s stock had a trading volume of 35,736 shares, compared to its average volume of 455,797. Curis has a twelve month low of $2.86 and a twelve month high of $17.49. The stock’s fifty day moving average price is $3.77 and its two-hundred day moving average price is $4.88. The stock has a market capitalization of $27.18 million, a P/E ratio of -0.41 and a beta of 3.42.

Institutional Investors Weigh In On Curis

An institutional investor recently raised its position in Curis stock. Focused Wealth Management Inc lifted its holdings in Curis, Inc. (NASDAQ:CRIS – Free Report) by 63.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 54,066 shares of the biotechnology company’s stock after buying an additional 20,908 shares during the period. Focused Wealth Management Inc owned about 0.92% of Curis worth $291,000 as of its most recent SEC filing. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

(Get Free Report)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.